Drug development cost estimates hard to swallow

February 2009
CMAJ: Canadian Medical Association Journal;2/3/2009, Vol. 180 Issue 3, p279
Academic Journal
The article discusses the cost estimates that pharmaceutical companies spent to bring a new drug to market. It is said that U.S. economists wrote the figures 802 000 000, which was according to the 2003 study, the number of U.S. dollars that the pharmaceutical industry spent for drug development. It is cited that medical experts agree that the cost of research and development in drug and the cost of clinical trials is rapidly rising. However, drug companies are sometimes accused of passing big figures to avoid public criticism.


Related Articles

  • Caution When Traveling Full Speed Ahead. Kaylynn Chiarello-Ebner // Pharmaceutical Technology;Jan2007, Vol. 31 Issue 1, p16 

    The author reflects on the implications of accelerated drug trials among pharmaceutical companies. She focuses on the disadvantage of the process wherein due to the being on fast track there is less time to scale up and fine tune the product, which is a key factor in drug development. She also...

  • Research Update.  // PharmaWatch: Biotechnology;Sep2006, Vol. 5 Issue 9, p9 

    The article reports developments on the research and development projects of several pharmaceutical companies worldwide. Amgen Inc. has started a large phase III study to evaluate the effectiveness of its drug Sensipar in treating patients with stage-five chronic kidney disease. Pain...

  • CLINICAL TRIALS NEWS.  // Applied Clinical Trials;Mar2006, Vol. 15 Issue 3, p16 

    No abstract available.

  • Data Analytics Takes on the Unexpected. Ruppel, Patricia // Applied Clinical Trials;Mar2006, Vol. 15 Issue 3, p79 

    No abstract available.

  • Approaching AFRICA. Rouse, Sharon; Mosqueira, Beatriz; Kermani, Faiz // Applied Clinical Trials;Mar2005, Vol. 14 Issue 3, p50 

    Focuses on the challenges in Africa that pharmaceutical companies should have a clear understanding for them to achieve their clinical trial objectives. Consideration on the diversity of the continent in terms of culture, custom and language; Variation in the standards of clinical trials in...

  • Real World Meets Clinical Claims. Stephenson, Hugo // Pharmaceutical Executive;Jul2004, Vol. 24 Issue 7, p32 

    Discusses factors key to the success of late-stage research in drug development in the United States. Demonstration of value of products to stakeholders; Trend among pharmaceutical companies of integrating the development and marketing sides of the business; Interview with Hugo Stephenson , a...

  • It's the Children Again. O'Donnell, Peter // Applied Clinical Trials;Oct2005, Vol. 14 Issue 10, p32 

    Details the controversy surrounding the European Parliament's first review of rules regarding pediatric research. Improvements in the proposal to accelerate the development of drugs for children, faster authorization procedures and shorter administrative delays to prevent unnecessary clinical...

  • Clinical Trials and CROs in the 21st Century. Hindin, Toby Jane // Applied Clinical Trials;Jun2004, Vol. 13 Issue 6, p12 

    The clinical research oversight (CRO) industry has reached a new stage of growth in clinical trials. There are now more than one thousand CRO with the largest number existing in Europe, followed by North America and Japan. While research and development costs are skyrocketing, product approvals...

  • Precautionary Principles. Corneliussen, Filippa // European Pharmaceutical Executive;May/Jun2006, p58 

    The article focuses on need for the biopharmaceutical industry to examine the oversight framework to regulate biomedical research and development activities in the private sector and to address how these laws and regulations affecting individual companies differ depending on the specific...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics